Department of Biochemistry, School of Medicine, Chang-Gung University, Taoyuan, Taiwan 333.
Mol Cell Proteomics. 2012 Apr;11(4):M111.011270. doi: 10.1074/mcp.M111.011270. Epub 2011 Dec 14.
The thyroid hormone, 3, 3',5-triiodo-l-thyronine (T(3)), regulates cell growth, development, differentiation, and metabolism via interactions with thyroid hormone receptors (TRs). However, the secreted proteins that are regulated by T(3) are yet to be characterized. In this study, we used the quantitative proteomic approach of stable isotope labeling with amino acids in cell culture coupled with nano-liquid chromatography-tandem MS performed on a LTQ-Orbitrap instrument to identify and characterize the T(3)-regulated proteins secreted in human hepatocellular carcinoma cell lines overexpressing TRα1 (HepG2-TRα1). In total, 1742 and 1714 proteins were identified and quantified, respectively, in three independent experiments. Among these, 61 up-regulated twofold and 11 down-regulated twofold proteins were identified. Eight proteins displaying increased expression and one with decreased expression in conditioned media were validated using Western blotting. Real-time quantitative RT-PCR further disclosed induction of plasminogen activator inhibitor-1 (PAI-1), a T(3) target, in a time-course and dose-dependent manner. Serial deletions of the PAI-1 promoter region and subsequent chromatin immunoprecipitation assays revealed that the thyroid hormone response element on the promoter is localized at positions -327/-312. PAI-1 overexpression enhanced tumor growth and migration in a manner similar to what was seen when T(3) induced PAI-1 expression in J7-TRα1 cells, both in vitro and in vivo. An in vitro neutralizing assay further supported a crucial role of secreted PAI-1 in T(3)/TR-regulated cell migration. To our knowledge, these results demonstrate for the first time that proteins involved in the urokinase plasminogen activator system, including PAI-1, uPAR, and BSSP4, are augmented in the extra- and intracellular space of T(3)-treated HepG2-TRα1 cells. The T(3)-regulated secretome generated in the current study may provide an opportunity to establish the mechanisms underlying T(3)-associated tumor progression and prognosis.
甲状腺激素 3,3',5-三碘-l-甲状腺原氨酸(T(3))通过与甲状腺激素受体(TRs)相互作用来调节细胞生长、发育、分化和代谢。然而,T(3)调节的分泌蛋白仍有待表征。在这项研究中,我们使用了稳定同位素标记与细胞培养中的氨基酸结合的定量蛋白质组学方法,结合在 LTQ-Orbitrap 仪器上进行的纳升液相色谱-串联 MS,来鉴定和表征在过表达 TRα1 的人肝癌细胞系(HepG2-TRα1)中分泌的 T(3)调节蛋白。在三个独立的实验中,分别鉴定和定量了 1742 和 1714 种蛋白质。其中,鉴定了 61 种表达上调两倍和 11 种表达下调两倍的蛋白质。使用 Western 印迹法验证了在条件培养基中表达增加的 8 种蛋白质和表达减少的 1 种蛋白质。实时定量 RT-PCR 进一步揭示了在时间过程和剂量依赖性方式下诱导了 T(3)靶标纤溶酶原激活物抑制剂-1(PAI-1)的表达。PAI-1 启动子区域的连续缺失以及随后的染色质免疫沉淀实验表明,启动子上的甲状腺激素反应元件位于-327/-312 位置。PAI-1 的过表达以类似于 T(3)诱导 J7-TRα1 细胞中 PAI-1 表达的方式增强了肿瘤的生长和迁移,无论是在体外还是体内。体外中和测定进一步支持了分泌型 PAI-1 在 T(3)/TR 调节细胞迁移中的关键作用。据我们所知,这些结果首次表明,尿激酶纤溶酶原激活系统中的蛋白质,包括 PAI-1、uPAR 和 BSSP4,在 T(3)处理的 HepG2-TRα1 细胞的细胞外和细胞内空间中增加。本研究中生成的 T(3)调节分泌组可能为建立 T(3)相关肿瘤进展和预后的机制提供机会。